Skip to search formSkip to main contentSkip to account menu

cilostazol

Known as: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one, Cilostazole, cilostazol [Chemical/Ingredient] 
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of… 
National Institutes of Health

Related topics

Related topics

20 relations

Broader (7)

Bronchodilator AgentsFibrinolytic AgentsNeuroprotective AgentsPhosphodiesterase 3 Inhibitors
CYP3A7 protein, humanCongestive heart failureGraft Occlusion, VascularHypersensitivity

Narrower (2)

OPC 13013Pletal

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Highly Cited
2010
Highly Cited
2010
Cilostazol enhances apoptosis of synovial cells from rheumatoid arthritis patients with inhibition of cytokine formation via Nrf2-linked heme oxygenase 1 induction.
OBJECTIVE To assess the effects of cilostazol in inhibiting proliferation and enhancing apoptosis in synovial cells from patients… 
Review
2008
Review
2008
Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury
Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase… 
Highly Cited
2006
Highly Cited
2006
Cilostazol Suppresses Superoxide Production and Expression of Adhesion Molecules in Human Endothelial Cells via Mediation of cAMP-Dependent Protein Kinase-Mediated Maxi-K Channel Activation
This study shows whether increased intracellular cAMP level by cilostazol is directly coupled to its maxi-K channel activation in… 
Highly Cited
2004
Highly Cited
2004
Functional characterization of large conductance calcium-activated K+ channel openers in bladder and vascular smooth muscle
Calcium activated K+ channels (KCa channels) are found in a variety of smooth muscle tissues, the most characterized of which are… 
Review
2001
Review
2001
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
2000
2000
6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2.
Highly Cited
1999
Highly Cited
1999
Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease
ObjectiveTo study the pharmacokinetics of cilostazol following single oral administration of 50 to 200mg in healthy young males… 
1999
1999
Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
1997
1997
Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)